Stay updated with breaking news from Nutrient Absorption. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Issuer: Immunic, Inc. / Key word(s): Study/Conference Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action 06.05.2023
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...
Issuer: Immunic, Inc. / Key word(s): Study results Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders 04.05.2023 / 12:30 CET/CEST The issuer is solely responsib...
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...
Issuer: Immunic, Inc. / Key word(s): Study results Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic